Objective
To achieve a high level of capital growth by investing worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
Management group
Frostrow Capital
Launch date
28/04/1995
Domicile
United Kingdom
Fund manager
Sven H. Borho, Trevor M. Polischuk
Dividend frequency
Semi-Annually
Wind-up provisions
Continuation vote at every fifth AGM, the next of which will be in 2024.
Market Cap (m) Total assets (m) Price (last close) NAV Discount / premium (%) Gearing (%) Dividend yield (%) Dividend dates Ongoing charge (%)
1,823.75 2,091.69 333.00 381.92 -12.81 1 0.93 Jun, Nov 0.8 (31/03/2023)
Scroll

Dividends

Dividends declared in last 12 months

Ex-Dividend date Payment date Dividend amount Special dividend Financial year
23/11/2023 11/01/2024 0.700 No 2024
08/06/2023 26/07/2023 2.400 No 2023
Scroll

Performance (%)

Return type 1 year 3 years 5 years 10 years
Worldwide Healthcare Trust Share price total return 9.2 -5.5 31.5 179.7
Biotechnology & Healthcare AIC sector Share price total return 4.5 -20.1 4.7 125.5
Scroll

Share structure

Number of shares
547,671,964

Traded volumes (number of shares)

  Yesterday 1 month 1 year 5 years
Total 1,337,801 26,775,606 341,024,287 1,360,994,507
Average N/A 1,284,200 1,346,690 1,079,050
Scroll

Traded values (m)

  Yesterday 1 month 1 year 5 years
Total 4.45 87.90 1,069.20 4,463.93
Average N/A 4.22 4.22 3.54
Scroll

Trading details

ISIN TIDM Traded currency Stock exchange
GB00BN455J50 WWH GBX London Stock Exchange - MAIN
Boerse Berlin
Chi-x Europe Limited
London Stock Exchange
Pink Sheets Llc (nqb)
Scroll

Top holdings

Data as at : 30/11/2023

Investment % of total assets
Novo Nordisk A/S Class B 7.5
Eli Lilly and Co 6.7
Boston Scientific Corp 6.0
AstraZeneca PLC 6.0
Intuitive Surgical Inc 5.1
Biogen Inc 4.0
Merck & Co Inc 3.7
Biomarin Pharmaceutical Inc 3.7
Daiichi Sankyo Co Ltd 3.5
Eisai Co Ltd 2.9

Morningstar logo Data provided by Morningstar.

FE fundinfo logo Company documents provided by FE fundinfo.